46 completed, 12 unknown, 8 recruiting, 8 terminated. 23 Phase 2, 21 Phase 1, 18 Phase 3, 15 Not applicable, 12 Phase 4.
Follow WW Domain-Containing Oxidoreductase: new trials by email Literature Review of WW Domain-Containing Oxidoreductase trials Research Report on WW Domain-Containing Oxidoreductase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma SHR-9839(sc) for Injection, SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion - Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 84 | 2026-09-07 | 2026-09-16 |
| Edaravone Dexborneol for Post-Stroke Epilepsy Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months., Placebo - Post-stroke Epilepsy, Post-stroke Seizure | Phase 3 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 160 | 2026-06-01 | 2026-05-22 |
| Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer. Letrozole - Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer | Phase 2 | Not yet recruiting | Cancer Care Hospital & Research Centre Foundation, Lahore | 126 | 2026-06-01 | 2026-02-20 |
| A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders JL18008 20 μg/kg, Placebo (for 20 μg/kg Group), JL18008 40 μg/kg - HIV Infections | Phase 1 / Phase 2 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 30 | 2026-05-26 | 2026-08-06 |
| A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors SHR-9839(sc) For Injection - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 70 | 2026-02-27 | 2026-03-20 |
| Unravelling the Effects of Nicotinamide/Pyrroloquinolone Quinone /Citicoline/Homotaurine Fixed Combination on Contrast Sensitivity, Quality of Life, and Reading Performance in Glaucoma Citicoline 500 MG (Optigen) for 4 months, citicoline 500 mg + nicotinamide 54 mg + PQQ 5 mg + Homotaurine 50 mg fixed combination tablet (Neuprozin mito) - Glaucoma | Not applicable | Completed | Università degli Studi 'G. d'Annunzio' Chieti e Pescara | 44 | 2025-11-01 | 2026-10-06 |
| Tailored Vs. Empirical Helicobacter Pylori Infection Treatment Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days - Helicobacter Pylori Infection | Phase 4 | Not yet recruiting | Manuel Coelho da Rocha | 160 | 2025-09-01 | 2024-12-20 |
| Movement Improves Brain Health and Cognition in Parkinson's Disease Aerobic exercise for >_75 minutes/week of vigorous aerobic exercise or >_ 150 minutes/week of moderate aerobic exercise in at least two weekly sessions, for 12 m - Parkinson Disease | Not applicable | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 150 | 2025-06-09 | 2025-12-23 |
| Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess Intravenous beta-lactam antimicrobial for 2 weeks Plus Intravenous Metronidazole (750 mg q 8 hourly) for 2 weeks, Tablet Cefixime (200 mg q 12 hourly) for 2 weeks Plus Tablet Metronidazole (800 mg q 8 hourly) for 2 weeks, Standard medical care - Liver Abscess | Phase 3 | Recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 220 | 2025-02-25 | 2025-04-13 |
| EFFECT OF CIRCUIT TRAINING ON BONE MINERAL DENSITY IN POST MENOPAUSAL PERIOD Group A (control group): It will be consisted of twenty two post menopausal women who will receive daily dosage of vitamin D3 supplement (600 IU/day) (Schleicher et al., 2016), for 6 week, 1-Dumbbells (set B08Z7SY6SP ,Gymbit , made in China) :They will be used for the treatment procedures of circuit training for all postmenopausal women in group B. Its surface is coated with vinyl fo - Post Menopausal, Osteoporosis | Not applicable | Recruiting | Cairo University | 44 | 2025-01-01 | 2025-04-30 |
| A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors MK-6204 (SKB535) for Injection - Advanced Solid Tumors | Phase 1 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 142 | 2024-12-12 | 2026-10-13 |
| To Evaluate the Safety of JL18008 JL18008 1 μg/kg, JL18008 5 μg/kg, JL18008 10 μg/kg - HIV Infections | Phase 1 | Completed | Jecho Biopharmaceuticals Co., Ltd. | 40 | 2024-06-13 | 2026-06-11 |
| Integration of Neurofunctional Phenotyping Into Investigation of CBT4CBT for AUD Stand-alone web-based cognitive behavioral therapy (CBT4CBT) for alcohol use disorder - Alcohol Abuse, Alcohol Use Disorder | Not applicable | Completed | Virginia Commonwealth University | 248 | 2024-04-10 | 2025-06-08 |
| Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge Amoxicillin 250 MG, Placebo, Amoxicillin 62.5mg - Penicillin Allergy | Phase 3 | Recruiting | James Tarbox, MD | 380 | 2024-02-03 | 2025-05-01 |
| A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects. AP026 (TQA2226) for injection, AP026 (TQA2226) for injection matching placebo - Diabetes Mellitus, Type 2 | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 14 | 2023-05-24 | 2026-04-22 |
| Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease - Sickle Cell Disease | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 30 | 2023-03-22 | 2023-09-21 |
| The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN Human umbilical cord mesenchymal stem cells, Interleukin-2 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 3 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 40 | 2022-10-01 | 2022-11-30 |
| The Effectiveness of Blended and Problem-based Learning to Improve the Competence of Geriatric Nursing Students The protocol of blended and problem-based learning, The traditional problem-oriented teaching model - Narrative Ethics | Not applicable | Unknown | National Taipei University of Nursing and Health Sciences | 100 | 2022-02-15 | 2022-03-22 |
| Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks., Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks. - Buruli Ulcer | Phase 2 | Unknown | Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID) | 140 | 2021-12-01 | 2024-05-16 |
| PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) - SARS-CoV-2 Infection | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 29 | 2021-04-05 | 2025-06-17 |
Showing 20 of 82. Sign in to see all of them.
Multiple Myeloma (5) · Recurrence (5) · Pericarditis (3) · Prostatic Neoplasms (3) · Alcoholism (2) · Bacterial Infections (2) · Breast Neoplasms (2) · Diabetes Mellitus, Type 2 (2) · Failure to Thrive (2) · HIV Infections (2) · Hypertension, Pulmonary (2) · Lung Diseases, Interstitial (2) · Neoplasm Metastasis (2) · Pulmonary Fibrosis (2) · Acute Coronary Syndrome (1)
Amgen (7) · Millennium Pharmaceuticals, Inc. (5) · Azienda Sanitaria Locale 3, Torino (3) · Assistance Publique - Hôpitaux de Paris (2) · Eli Lilly and Company (2) · Jecho Biopharmaceuticals Co., Ltd. (2) · Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) (2) · Seoul National University Hospital (2) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · University of Pennsylvania (2) · University of Zurich (2) · AboutSkin Dermatology and DermSurgery, PC (1) · Acrotech Biopharma Inc. (1) · Boehringer Ingelheim (1) · Buddhist Tzu Chi General Hospital (1)
United States (31) · China (10) · Italy (8) · Canada (6) · United Kingdom (6) · France (5) · South Korea (5) · Taiwan (4) · Brazil (3) · Germany (3) · Netherlands (3) · Australia (2) · Czechia (2) · Denmark (2) · Greece (2)
Konrad E Bloch, MD (2) · Alberto Albanese, MD (1) · Amy Kimball, MD (1) · Antonio J Delgado-Leon, MD (1) · Antonio R Delgado-Almeida, MD, FAHA, FACC, APS (1) · Carlos L Delgado-Leon, MD (1) · Cheng Zhao, Doctor (1) · Christiane Macedo, doctor (1) · Dace Svikis (1)
PMID 11168709, PMID 12490869, PMID 17029531, PMID 19581264, PMID 20805112, PMID 21040020, PMID 21300243, PMID 21809142, PMID 21873705, PMID 21884871, PMID 22090167, PMID 22555973, PMID 22833546, PMID 23183437, PMID 23233719, PMID 23680589, PMID 23916321, PMID 23992557, PMID 25106680, PMID 25155588, PMID 25664595, PMID 29025834, PMID 29026685, PMID 30533343, PMID 31388932, PMID 32074444, PMID 32141619, PMID 32199493, PMID 32281185, PMID 32298512, PMID 32302790, PMID 32369639, PMID 32766383, PMID 32886764, PMID 33590573, PMID 33596829, PMID 33667124, PMID 33945661, PMID 33971847, PMID 35804454, PMID 36215217, PMID 36871230, PMID 38573915, PMID 38761816, PMID 38786579, PMID 40160090, PMID 41509615, PMID 41603130, PMID 42104494, PMID 42234929
2014 (2), 1DP3DK094292-01 (1), P50AA010761 (1), R21DA026754 (1)